← Back to Search

Antipsychotic

Quetiapine vs Trazodone for Postpartum Depression

Phase < 1

Waitlist Available

Research Sponsored by Lawson Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Outpatients between ages 18 and 45 years who are within 6 months of delivering a child and have a DSM-5-TR diagnosis of major depressive disorder (MDD) with peripartum onset

A 17-item Hamilton Depression Rating Scale (HDRS) score of >18 at both the screening and baseline visits

Must not have

Women with schizophrenia spectrum or other psychotic disorders

Women with eating disorders

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 weeks

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to study the effectiveness and side effects of two drugs, quetiapine and trazodone, in treating postpartum depression. Postpartum depression affects about 17%

Who is the study for?

This trial is for women who have recently given birth and are experiencing postpartum depression. Participants should not have been treated yet for their condition. The study aims to help those struggling with sleeplessness and depressive symptoms after delivery.

What is being tested?

The study is comparing the effectiveness of two drugs, Quetiapine and Trazodone, in treating postpartum depression. It will assess which drug better improves mental health outcomes for new mothers suffering from this condition.

What are the potential side effects?

Possible side effects of Quetiapine may include drowsiness, weight gain, dry mouth, or constipation. Trazodone can also cause dizziness or blurred vision among other potential side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18-45, had a baby within the last 6 months, and have been diagnosed with depression starting around the time of birth.

Select...

My depression score is above 18 on the HDRS scale.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with schizophrenia or a similar psychotic disorder.

Select...

I am a woman with an eating disorder.

Select...

I am a woman dealing with substance addiction issues.

Select...

I have a health condition that makes it unsafe for me to use quetiapine.

Select...

I am a woman who cannot tolerate or did not respond to quetiapine.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hamilton Depression Rating Scale

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: QuetiapineActive Control1 Intervention

Participants will be started on trazodone 12.5 mg or quetiapine 6.25 mg in identical opaque gelatin capsules at bedtime. The doses will be increased to a maximum of 50 mg for trazodone and 25 mg for quetiapine.

Group II: TrazadoneActive Control1 Intervention

0 / 7Eligibility criteria met